Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Phase 1

Completed

Conditions: Stage IV Non-Small Cell Lung Cancer

Interventions: Drug: Necitumumab
Drug: Pembrolizumab

First Posted Date: 2015-05-22

Last Posted Date: 2020-10-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 71

Registration Number: NCT02451930

Locations: 🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sunto-Gun, Japan
🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

and more 1 locations

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Phase 3

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Olaratumab
Drug: Placebo
Drug: Doxorubicin

First Posted Date: 2015-05-22

Last Posted Date: 2024-10-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 509

Registration Number: NCT02451943

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Georgia Cancer Specialists PC, Atlanta, Georgia, United States
🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia

and more 106 locations

A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer Stage IV

Interventions: Drug: Abemaciclib
Drug: Docetaxel

First Posted Date: 2015-05-21

Last Posted Date: 2021-08-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 159

Registration Number: NCT02450539

Locations: 🇺🇸
Vista Oncology Inc. PS, Olympia, Washington, United States
🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of
🇷🇺
Volgograd regional clinical oncology dispensary, Volzhsky, Russian Federation

and more 6 locations

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Phase 2

Completed

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Ramucirumab

First Posted Date: 2015-05-14

Last Posted Date: 2020-06-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 164

Registration Number: NCT02443883

Locations: 🇺🇸
USC Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States

and more 6 locations

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Phase 1

Completed

Conditions: Gastric Adenocarcinoma
Biliary Tract Cancer
Carcinoma, Transitional Cell
Non-small Cell Lung Cancer
Adenocarcinoma of the Gastroesophageal Junction

Interventions: Drug: Ramucirumab
Drug: Pembrolizumab

First Posted Date: 2015-05-13

Last Posted Date: 2024-07-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 175

Registration Number: NCT02443324

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

and more 4 locations

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: LY3023414
Drug: Necitumumab

First Posted Date: 2015-05-13

Last Posted Date: 2020-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 31

Registration Number: NCT02443337

Locations: 🇺🇸
Southern Cancer Center, P.C., Mobile, Alabama, United States
🇺🇸
Comprehensive Cancer Care and Research Institute of Colorado, Englewood, Colorado, United States
🇺🇸
Chattanooga Oncology Hematology, Chattanooga, Tennessee, United States

and more 10 locations

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Early-Stage Breast Carcinoma
Hormone Receptor Positive Tumor

Interventions: Drug: Abemaciclib
Drug: Loperamide
Drug: Anastrozole

First Posted Date: 2015-05-12

Last Posted Date: 2020-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 224

Registration Number: NCT02441946

Locations: 🇺🇸
Millennium Oncology, Houston, Texas, United States
🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Taipei, Taiwan
🇺🇸
Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States

and more 28 locations

A Study of Galcanezumab in Participants With Chronic Cluster Headache

Phase 3

Completed

Conditions: Chronic Cluster Headache

Interventions: Drug: Galcanezumab 300 mg
Drug: Placebo

First Posted Date: 2015-05-08

Last Posted Date: 2020-08-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 240

Registration Number: NCT02438826

Locations: 🇺🇸
Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Etienne Cedex 2, France
🇺🇸
Southwestern Medical Center - Dallas, Dallas, Texas, United States

and more 17 locations

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:

Phase 3

Completed

Conditions: Acute Migraine

Interventions: Drug: Lasmiditan 100 mg
Drug: Lasmiditan 200 mg
Drug: Placebo (matches lasmiditan doses)

First Posted Date: 2015-05-08

Last Posted Date: 2019-12-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2231

Registration Number: NCT02439320

Locations: 🇺🇸
Allied Clinical Research, Gold River, California, United States
🇺🇸
Comprehensive Clinical Development- Washington DC, Washington, District of Columbia, United States
🇺🇸
Radiant Research, Inc, Dallas, Texas, United States

and more 72 locations

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

Phase 3

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Ramucirumab
Drug: Placebo

First Posted Date: 2015-05-06

Last Posted Date: 2023-01-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 399

Registration Number: NCT02435433

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇨🇳
"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Tainan, Taiwan

and more 14 locations

Home Terms & Conditions Privacy Policy